Cargando…
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control,...
Autores principales: | Eligar, Vinay S, Bain, Stephen C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770622/ https://www.ncbi.nlm.nih.gov/pubmed/24039399 http://dx.doi.org/10.2147/DDDT.S32331 |
Ejemplares similares
-
Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
por: Arjona Ferreira, Juan Camilo, et al.
Publicado: (2013) -
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
por: Kothny, Wolfgang, et al.
Publicado: (2015) -
The confluent hypergeometric function with special emphasis on its applications
por: Buchholz, Herbert
Publicado: (1969) -
Recovery in Special Emphasis Populations
por: Wagner, Eric F., et al.
Publicado: (2020) -
Pycnodysostosis with Special Emphasis on Dentofacial Characteristics
por: Khoja, Aisha, et al.
Publicado: (2015)